Celgene-CELG Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Celgene-CELG

CELG 108.24

0.0%

Nov 22 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: straight life	9/6/2012 11:53:36 AM
	Read Replies (1) of 804

WAKE UP, Everybody!: 15 things CELG investors & analysts are missing or underestimating imo (its not just Apremilast)...... (I found this on yahoo! link is on the bottom. I'm long, on a beautiful day to be long = +3.24 ) 1) Apremilast is underestimated in maybe 4 indications . Talk to Dermatologists and they will tell you they are really in need of an oral PDE-4 inhibitor so they can move away from drugs like $3 billion a year injectable biologic Enbrel which has links to lymphoma/leukemia and causes horrible infections in many patients 2) Abraxane in Pancreatic Cancer – if it simply shows efficacy similar to Ph 2 it will become the gold std of care in this tough disease. 500 patients were in this trial for 20 months at least and it still has not reached the 600 event limit for interim look/halt 3) Margins - best gross margins in the ENTIRE S&P 500 not just healthcare. Q2 showed amazing margin delivered and most analysts didn’t even mention it. 4) P&L leverage and undervalued earnings growth - enormous "right to the bottom line" effect of international and indication expansion of Revlimid - a drug with 95% gross margins with an industry low global tax rate (REALLY BEING MISSED BY MANY). PEG ratio is ridiculously low because of SPM and "1 drug" #$%$ Soon 5 separate billion $ a yr drugs will be apparent. 5) Tax Strategy/Rates - amazing effect of Swiss plant 0% tax 6) Vidaza generic timing – now guaranteed through another yr end no generic sales in US. 7) International Vidaza sales pace - heading to $1 billion a yr + imo - still yrs and yrs of exclusivity in EU 8) Possibility of CHMP approval earlier than people expect in front line 9) MM020 international results (Huge international Rev-Dex front line trial) 10) China approval this yr for Revlimid and the 100-200 million+ private pay/private insurance people who could immediately buy 11) International Expansion - Mexico-Brazil-Russia-Turkey-South America-So Korea-etc 12) Indication expansion (first NHL approval coming sooner than people think) 13) Pomalidomide in US (Feb PDUFA in US - FDA been approving cancer drugs ahead of pdufa) 14) Pomalidomide in EU - it truly looks like EU wants to approve this on Ph 2 data - amazing 15) What I call the "shadow pipeline" of the small biotech companies Celgene has partnered with Acceleron, GlobleImmune, Agios, Array, etc. Only Rodman has been talking about this promise. Love equity and milestone plays for early stage pipeline that doesn't hit R&D expense heavily. Sentiment: Strong Buy finance.yahoo.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next